TYRA

AI Memo

Tyra Biosciences

As of 2026-10-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

SURF302 dose and Phase 3 development decisions • 2027-01-24

Base target: $19 / p=50% prob

Biggest risk

SURF302's small early cohorts may overstate later efficacy, while durability, optimal dose, Phase 3 design and achondroplasia benefit remain unproven. The September offering was expected to raise roughly $400 million gross but entails substantial share and warrant issuance; the filing did not itself establish closing. [#PR-EARNINGS-2026-09-09] [#8-K-2026-09-15]

Invalidation

Break below $9 or thesis failure.

What would change my mind?

A reproducible, durable SURF302 response with acceptable chronic-dosing safety could support the planned adjuvant Phase 3 path; favorable BEACH301 data would add a distinct indication. TYRA reported $353.9 million of cash, equivalents and marketable securities at Q2 2026. [#PR-EARNINGS-2026-09-09] [#SEC-8K-2026-08-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-26

Base target

$19

p=50%

Bull target

$33

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

SURF303 low-grade UTUC development
A reproducible, durable SURF302 response with acceptable chronic-dosing safety could support the planned adjuvant Phase 3 path; favorable BEACH301 data would add a distinct indication.
TYRA reported $353.9 million of cash, equivalents and marketable securities at Q2 2026.

BearKey bullets

A disappointing BEACH301 growth or safety signal could weaken the achondroplasia opportunity.
[#SEC-8K-2026-08-04]
SURF302 efficacy rests on small early cohorts; response durability and Phase 3 reproducibility are unresolved.

WatchKey bullets

SURF302 dose and Phase 3 development decisions

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $19 (p=50%)

Target spread vs base: +74% / -53%

Scenario probabilities

Bull Target: $33 (p=20%)Base Target: $19 (p=50%)Bear Target: $9 (p=30%)

Commentary

Coverage described a sharp negative reaction to the September SURF302 data, notwithstanding TYRA's favorable interpretation of early responses. The October 23 price anchor is $20.45; the packet does not establish whether the initial reaction held or reversed on a comparable basis. No reliable post-readout target revisions, social coverage, options skew, short-interest or employee score were supplied. The negative deterministic directional prior and thin forward evidence favor monitoring rather than treating financing as clinical de-risking.

As of 2026-10-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

SURF303 low-grade UTUC development

Scenarios

Bull Target (Scenario probability)

$33 / p=20% prob

Base Target (Scenario probability)

$19 / p=50% prob

Bear Target (Scenario probability)

$9 / p=30% prob

Analysis 2026-10-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.30

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-01-24
SURF302 dose and Phase 3 development decisions
Initial Phase 2 data supported 60 mg daily for TYRA's planned adjuvant strategy, but the 64% best-overall complete-response rate came from just 14 evaluable patients across single- and multiple-lesion groups. Subsequent dose selection and trial design must establish whether that early signal can translate into durable benefit; no decision date is confirmed. [#PR-EARNINGS-2026-09-09]
Prob 65.00% • Move 18.00% • Priced-in 45.00%
EVENT2027-03-31
BEACH301 achondroplasia readout
TYRA expected initial Phase 2 safety-sentinel data from approximately 25 children, including a fifth dose level, by the end of Q1 2027. Safety and growth-velocity evidence will determine whether dabogratinib has a credible second development path. [#SEC-8K-2026-08-04]
Prob 75.00% • Move 20.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

SURF303 low-grade UTUC development
2027-10-26
TYRA is studying dabogratinib in low-grade upper-tract urothelial carcinoma. The reported three-month complete response in the first treated patient is anecdotal; a larger dataset is needed before assigning meaningful efficacy value. [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-09-09]
Prob 60% • Move 15% • Priced-in 20%

Risks

A disappointing BEACH301 growth or safety signal could weaken the achondroplasia opportunity. [#SEC-8K-2026-08-04]
SURF302 efficacy rests on small early cohorts; response durability and Phase 3 reproducibility are unresolved. [#PR-EARNINGS-2026-09-09]
TYRA remains a clinical-stage issuer with development spending and no established commercial uptake in the supplied evidence.
The September financing adds potential dilution through common shares and pre-funded warrants; the cited 8-K described an expected, not confirmed, close. [#8-K-2026-09-15]

Peers

Symbol	Summary
INBX	Similarly sized development-stage biotech, but its programs are not a direct FGFR3 or bladder-cancer comparison; use only for broad clinical-risk context.
AAPG	Similar supplied market capitalization, but a loose therapeutic and geographic comparison. It does not provide a reliable TYRA valuation multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-26